COFCO BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.58 CNY | -0.15% |
|
+4.44% | -0.90% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,194 | 15,710 | 20,280 | 15,594 | 12,270 | - | - |
| Enterprise Value (EV) 1 | 12,194 | 15,710 | 20,280 | 15,594 | 12,270 | 12,270 | 12,270 |
| P/E ratio | 20.6 x | 26.2 x | 17.8 x | 14.7 x | 165 x | 25.3 x | 17.3 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.63 x | 0.79 x | 0.86 x | 0.78 x | 0.6 x | 0.59 x | 0.57 x |
| EV / Revenue | 0.63 x | 0.79 x | 0.86 x | 0.78 x | 0.6 x | 0.59 x | 0.57 x |
| EV / EBITDA | 11 x | 12.4 x | 11.1 x | 8.63 x | 16 x | 10.3 x | 8.92 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 1.24 x | 1.51 x | 1.78 x | 1.29 x | 1.16 x | 1.12 x | 1.07 x |
| Nbr of stocks (in thousands) | 1,847,644 | 1,865,764 | 1,865,718 | 1,865,274 | 1,864,721 | - | - |
| Reference price 2 | 6.600 | 8.420 | 10.87 | 8.360 | 6.580 | 6.580 | 6.580 |
| Announcement Date | 4/13/20 | 4/14/21 | 4/28/22 | 4/14/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 19,472 | 19,909 | 23,469 | 19,918 | 20,404 | 20,659 | 21,543 |
| EBITDA 1 | 1,105 | 1,268 | 1,833 | 1,808 | 767 | 1,197 | 1,376 |
| EBIT 1 | 660 | 806.3 | 1,381 | 1,350 | 75 | 501 | 689 |
| Operating Margin | 3.39% | 4.05% | 5.88% | 6.78% | 0.37% | 2.43% | 3.2% |
| Earnings before Tax (EBT) 1 | 666.3 | 801.9 | 1,383 | 1,360 | 89 | 519 | 709 |
| Net income 1 | 592.8 | 593.1 | 1,133 | 1,059 | 81 | 488 | 705 |
| Net margin | 3.04% | 2.98% | 4.83% | 5.32% | 0.4% | 2.36% | 3.27% |
| EPS 2 | 0.3209 | 0.3209 | 0.6109 | 0.5700 | 0.0400 | 0.2600 | 0.3800 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/13/20 | 4/14/21 | 4/28/22 | 4/14/23 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 6.21% | 5.86% | 10.4% | 9.02% | 0.8% | 4.4% | 6.2% |
| ROA (Net income/ Total Assets) | - | - | 5.88% | - | 0.5% | 2.9% | 4% |
| Assets 1 | - | - | 19,273 | - | 16,200 | 16,828 | 17,625 |
| Book Value Per Share 2 | 5.320 | 5.570 | 6.110 | 6.490 | 5.650 | 5.890 | 6.140 |
| Cash Flow per Share | 1.980 | -1.560 | 2.600 | 0.3800 | - | - | - |
| Capex 1 | 901 | - | 839 | - | 200 | 200 | 200 |
| Capex / Sales | 4.63% | - | 3.58% | - | 0.98% | 0.97% | 0.93% |
| Announcement Date | 4/13/20 | 4/14/21 | 4/28/22 | 4/14/23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.58
CNY
Average target price
8
CNY
Spread / Average Target
+21.58%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.90% | 1.7B | |
| -1.96% | 74.28B | |
| +0.05% | 46.91B | |
| +2.38% | 32.93B | |
| +7.54% | 17.78B | |
| -6.58% | 12.09B | |
| +12.48% | 11.88B | |
| -0.23% | 10.66B | |
| +3.37% | 9.55B | |
| +5.01% | 8.28B |
- Stock Market
- Equities
- 000930 Stock
- Financials COFCO Biotechnology Co., Ltd.